A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
30 de outubro de 2026 atualizado por: Teresa Boitano, University of Alabama at Birmingham
Pilot Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
This is a pilot project to determine the safety and feasibility of using panitumumab-IRDye800 to detect cancerous tissue compared to normal surrounding tissue in participants with ovarian cancer undergoing surgical resection. This study is an extension of the work previously done using this agent in patients with squamous cell carcinoma (SCC) of the head and neck, exploring its utility in a different cancer type.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Descrição detalhada
The study is an open label, single site, Phase I study to determine the safety and feasibility of using conjugated panitumumab-IRDye800 in patients with ovarian cancer undergoing surgical resection. Tumor to background ratios (TBRs) will be determined by comparing fluorescence intensity of tumor tissue to grossly normal tissue in the field. The presence of tumor tissue and fluorescence will be confirmed by histopathologic analysis.
Panitumumab-IRDye800CW has a toxicity and pharmacodynamic profile that matches the parent compound. In this study, patients will receive a 50mg flat dose of panitumumab-IRdye800 without a loading dose of panitumumab alone, which was found in the Phase I study of patient with head and neck cancer to be the safest and most cost-effective dose in a dose-range escalation study with high sensitivity, specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) for fluorescence detection of tumor compared to normal background tissue. This infusion will occur 24-72 hours prior to planned surgery.
Tipo de estudo
Intervencional
Inscrição (Estimado)
6
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Michelle Osoinak, BSN, RN, CNOR
- Número de telefone: 205-539-2903
- E-mail: mosoinak@uabmc.edu
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham
-
Subinvestigador:
- Jason Warram, PhD
-
Investigador principal:
- Teresa Boitano, MD
-
Contato:
- Michelle Osoinak, BSN, RN, CNOR
- Número de telefone: 205-539-2903
- E-mail: mosoinak@uabmc.edu
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Fêmea
Descrição
Inclusion Criteria:
-
Biopsy-confirmed diagnosis of ovarian cancer.
-
Diagnosis of any stage.
-
Diagnosis of any histology.
-
Planning to undergo surgical resection via any modality (i.e., open, laparoscopic, robotic) with primary cytoreduction or interval debulking following neoadjuvant chemotherapy.
-
Age ≥ 18 years
-
ECOG 1
-
Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
- Hemoglobin ≥ 9 gm/dL
- Absolute Neutrophil Count ≥ 1500
- White Blood Cell count > 3000/mm3
- Platelet count ≥ 100,000/mm3
- Serum creatinine ≤ 1.5 times upper reference range
Exclusion Criteria:
- Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
- Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
- History of infusion reactions to any monoclonal antibody therapies
- Pregnant or breast-feeding
- Evidence of QT prolongation on pretreatment EKG (greater than 440 ms in males or greater than 450 ms in females)
- Magnesium or potassium lower than the normal institutional values
- Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
- Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
- TSH > 13 micro International Units/mL
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Patients requiring surgical resection of ovarian cancer
Enrolled patients will receive a one-time IV infusion of 50mg of the investigational agent, panitumumab-IRDye800, 24-72 hours prior to the scheduled surgical resection. Participants will be monitored using standard clinical parameters to evaluate for toxicity. Participants will be observed immediately after infusion of the study drug. The following observations and tests shall be performed after treatment to identify both acute and late treatment specific toxicity: vital signs, physical exam, toxicity grading, assignment of performance status, hematology, and blood chemistries (complete metabolic profile to include magnesium and phosphorus). NCI Common Toxicity Criteria v5.0 will be used for grading of toxicity. |
Single IV systemic infusion of panitumumab-IRDye800 and NIR imaging of cancer during and after surgical resection. Enrolled patients will receive a one-time IV infusion of 50mg of the investigational agent, panitumumab-IRDye800, 24-72 hours prior to the scheduled surgical resection. All appropriate labs, tests, and safety monitoring will occur as outlined in Section 8.1. Participants will be monitored using standard clinical parameters to evaluate for toxicity. Participants will be observed immediately after infusion of the study drug. The following observations and tests shall be performed after treatment to identify both acute and late treatment specific toxicity: vital signs, physical exam, toxicity grading, assignment of performance status, hematology, and blood chemistries (complete metabolic profile to include magnesium and phosphorus). NCI Common Toxicity Criteria v5.0 will be used for grading of toxicity. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Dose limiting toxicity (DLT)
Prazo: up to 15 days after infusion
|
Dose limiting toxicity (DLT) defined as any grade 2 or greater toxicity that is considered definitely related to the study drug, considered clinically significant by the Principal Investigator, and occurs within 15 days of receiving treatment. |
up to 15 days after infusion
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Teresa Boitano, MD, University of Alabama at Birmingham
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Rosenthal EL, Warram JM, de Boer E, Basilion JP, Biel MA, Bogyo M, Bouvet M, Brigman BE, Colson YL, DeMeester SR, Gurtner GC, Ishizawa T, Jacobs PM, Keereweer S, Liao JC, Nguyen QT, Olson JM, Paulsen KD, Rieves D, Sumer BD, Tweedle MF, Vahrmeijer AL, Weichert JP, Wilson BC, Zenn MR, Zinn KR, van Dam GM. Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. J Nucl Med. 2016 Jan;57(1):144-50. doi: 10.2967/jnumed.115.158915. Epub 2015 Oct 8.
- Marshall MV, Draney D, Sevick-Muraca EM, Olive DM. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol. 2010 Dec;12(6):583-94. doi: 10.1007/s11307-010-0317-x.
- Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan MA, Powell MA, Tseng JH, Lopez AS, Wenham RM. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). J Clin Oncol. 2023 Jan 10;41(2):276-284. doi: 10.1200/JCO.22.00291. Epub 2022 Sep 7.
- Agnes RS, Broome AM, Wang J, Verma A, Lavik K, Basilion JP. An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor. Mol Cancer Ther. 2012 Oct;11(10):2202-11. doi: 10.1158/1535-7163.MCT-12-0211. Epub 2012 Jul 17.
- Agusti N, Barajas K, Rauh-Hain JA. Minimally invasive surgery in advanced and recurrent ovarian cancer: current evidence and future directions. Curr Opin Oncol. 2025 Sep 1;37(5):478-486. doi: 10.1097/CCO.0000000000001162. Epub 2025 Jun 5.
- Andrades P, Rosenthal EL, Carroll WR, Baranano CF, Peters GE. Zygomatic-maxillary buttress reconstruction of midface defects with the osteocutaneous radial forearm free flap. Head Neck. 2008 Oct;30(10):1295-302. doi: 10.1002/hed.20874.
- Bailey L, Stone LD, Gonzalez ML, Thomas CM, Jeyarajan H, Warram JM, Panuganti B. Panitumumab-IRDye800 Improves Laryngeal Tumor Mapping During Transoral Laser Microsurgery. Laryngoscope. 2024 Apr;134(4):1837-1841. doi: 10.1002/lary.31078. Epub 2023 Oct 20.
- Barnes TG, Volpi D, Cunningham C, Vojnovic B, Hompes R. Improved urethral fluorescence during low rectal surgery: a new dye and a new method. Tech Coloproctol. 2018 Feb;22(2):115-119. doi: 10.1007/s10151-018-1757-6. Epub 2018 Feb 19.
- Chiu CH, Chao YK, Liu YH, Wen CT, Chen WH, Wu CY, Hsieh MJ, Wu YC, Liu HP. Clinical use of near-infrared fluorescence imaging with indocyanine green in thoracic surgery: a literature review. J Thorac Dis. 2016 Oct;8(Suppl 9):S744-S748. doi: 10.21037/jtd.2016.09.70.
- Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen GA. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res. 2011 Dec 1;1(1):31. doi: 10.1186/2191-219X-1-31.
- Day KE, Beck LN, Deep NL, Kovar J, Zinn KR, Rosenthal EL. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope. 2013 Nov;123(11):2681-9. doi: 10.1002/lary.24102. Epub 2013 Apr 24.
- Day KE, Beck LN, Heath CH, Huang CC, Zinn KR, Rosenthal EL. Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma. Cancer Biol Ther. 2013 Mar;14(3):271-7. doi: 10.4161/cbt.23300. Epub 2013 Jan 8.
- Day KE, Sweeny L, Kulbersh B, Zinn KR, Rosenthal EL. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol. 2013 Dec;15(6):722-9. doi: 10.1007/s11307-013-0652-9.
- de Boer E, Warram JM, Tucker MD, Hartman YE, Moore LS, de Jong JS, Chung TK, Korb ML, Zinn KR, van Dam GM, Rosenthal EL, Brandwein-Gensler MS. In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. Sci Rep. 2015 Jun 29;5:10169. doi: 10.1038/srep10169.
- de Wit JG, Vonk J, Voskuil FJ, de Visscher SAHJ, Schepman KP, Hooghiemstra WTR, Linssen MD, Elias SG, Halmos GB, Plaat BEC, Doff JJ, Rosenthal EL, Robinson D, van der Vegt B, Nagengast WB, van Dam GM, Witjes MJH. EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial. Nat Commun. 2023 Aug 16;14(1):4952. doi: 10.1038/s41467-023-40324-8.
- DiLoreto DA Jr, Das T, del Cerro C, Cox C, del Cerro M. Fluorescein as a marker for subretinal transplantation of human fetal neural retina. Curr Eye Res. 1997 Nov;16(11):1159-65. doi: 10.1076/ceyr.16.11.1159.5100.
- DSouza AV, Lin H, Henderson ER, Samkoe KS, Pogue BW. Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging. J Biomed Opt. 2016 Aug 1;21(8):80901. doi: 10.1117/1.JBO.21.8.080901.
- Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. doi: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7.
- Gao RW, Teraphongphom N, de Boer E, van den Berg NS, Divi V, Kaplan MJ, Oberhelman NJ, Hong SS, Capes E, Colevas AD, Warram JM, Rosenthal EL. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics. 2018 Mar 28;8(9):2488-2495. doi: 10.7150/thno.24487. eCollection 2018.
- Gao RW, Teraphongphom NT, van den Berg NS, Martin BA, Oberhelman NJ, Divi V, Kaplan MJ, Hong SS, Lu G, Ertsey R, Tummers WSFJ, Gomez AJ, Holsinger FC, Kong CS, Colevas AD, Warram JM, Rosenthal EL. Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. Cancer Res. 2018 Sep 1;78(17):5144-5154. doi: 10.1158/0008-5472.CAN-18-0878. Epub 2018 Jul 2.
- Garcia-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol. 2019 Sep 20;9:849. doi: 10.3389/fonc.2019.00849. eCollection 2019.
- Gleysteen JP, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL. Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther. 2007 Aug;6(8):1181-5. doi: 10.4161/cbt.6.8.4379. Epub 2007 May 3.
- Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck. 2008 Jun;30(6):782-9. doi: 10.1002/hed.20782.
- Gul Z, Henary M. Pafolacianine, the magic wand of intraoperative imaging of folate-receptor positive ovarian cancer. Ann Transl Med. 2023 Oct 25;11(11):394. doi: 10.21037/atm-23-467. Epub 2023 Mar 1. No abstract available.
- Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol. 2019 Feb;141(3):479-486. doi: 10.1007/s11060-019-03098-y. Epub 2019 Jan 14.
- Haglund MM, Berger MS, Hochman DW. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery. 1996 Feb;38(2):308-17. doi: 10.1097/00006123-199602000-00015.
- Heath CH, Deep NL, Sweeny L, Zinn KR, Rosenthal EL. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol. 2012 Nov;19(12):3879-87. doi: 10.1245/s10434-012-2435-y. Epub 2012 Jun 6.
- Helman EE, Newman JR, Dean NR, Zhang W, Zinn KR, Rosenthal EL. Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther. 2010 Jul 15;10(2):166-71. doi: 10.4161/cbt.10.2.12164.
- Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed Dosing of Monoclonal Antibodies in Oncology. Oncologist. 2017 Oct;22(10):1212-1221. doi: 10.1634/theoncologist.2017-0167. Epub 2017 Jul 28.
- Hinni ML, Ferlito A, Brandwein-Gensler MS, Takes RP, Silver CE, Westra WH, Seethala RR, Rodrigo JP, Corry J, Bradford CR, Hunt JL, Strojan P, Devaney KO, Gnepp DR, Hartl DM, Kowalski LP, Rinaldo A, Barnes L. Surgical margins in head and neck cancer: a contemporary review. Head Neck. 2013 Sep;35(9):1362-70. doi: 10.1002/hed.23110. Epub 2012 Sep 3.
- Hui-Chou HG, Thakkar MY, Means KR Jr, Higgins JP. A Prospective Pilot Study of Vascular Assessment of the Upper Extremity With Laser Angiography. Hand (N Y). 2020 Nov;15(6):870-876. doi: 10.1177/1558944719837023. Epub 2019 Mar 21.
- Kajiyama D, Kubo Y, Shigeno T, Sato K, Fujiwara N, Daiko H, Fujita T. New quantitative blood flow assessment of gastric conduit with indocyanine green fluorescence in oesophagectomy: prospective cohort study. BJS Open. 2025 Oct 30;9(6):zraf135. doi: 10.1093/bjsopen/zraf135.
- Keizers B, Nijboer TS, van der Fels CAM, van den Heuvel MC, van Dam GM, Kruijff S, Jan de Jong I, Witjes MJH, Voskuil FJ, Gorpas D, Browne WR, van der Zaag PJ. Systematic comparison of fluorescence imaging in the near-infrared and shortwave-infrared spectral range using clinical tumor samples containing cetuximab-IRDye800CW. J Biomed Opt. 2025 Jan;30(Suppl 1):S13708. doi: 10.1117/1.JBO.30.S1.S13708. Epub 2024 Nov 15.
- Kobayashi T, Komatsu T, Kamiya M, Campos C, Gonzalez-Gaitan M, Terai T, Hanaoka K, Nagano T, Urano Y. Highly activatable and environment-insensitive optical highlighters for selective spatiotemporal imaging of target proteins. J Am Chem Soc. 2012 Jul 11;134(27):11153-60. doi: 10.1021/ja212125w. Epub 2012 Jun 28.
- Korb ML, Warram JM, Grudzinski J, Weichert J, Jeffery J, Rosenthal EL. Breast cancer imaging using the near-infrared fluorescent agent, CLR1502. Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00040.
- Kulbersh BD, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg. 2007 May;133(5):511-5. doi: 10.1001/archotol.133.5.511.
- Langstraat C, Cliby WA. Considerations in the surgical management of ovarian cancer in the elderly. Curr Treat Options Oncol. 2013 Mar;14(1):12-21. doi: 10.1007/s11864-012-0216-2.
- Lehane A, Polites SF, Dodd A, Goldstein SD, Lautz TB. Let it glow: Intraoperative visualization of pulmonary metastases using pafolacianine, a next-generation fluorescent agent, for young adults undergoing pulmonary metastasectomy. Pediatr Blood Cancer. 2024 Nov;71(11):e31293. doi: 10.1002/pbc.31293. Epub 2024 Aug 27.
- Li DH, Smith BD. Deuterated Indocyanine Green (ICG) with Extended Aqueous Storage Shelf-Life: Chemical and Clinical Implications. Chemistry. 2021 Oct 19;27(58):14535-14542. doi: 10.1002/chem.202102816. Epub 2021 Sep 24.
- Litchinko A, Meyer J, Buhler L, Ris F, Adamina M. Fluorescence indocyanine green (ICG) for sentinel-lymph-node mapping in colorectal cancer: a systematic review. Langenbecks Arch Surg. 2025 Jul 1;410(1):202. doi: 10.1007/s00423-025-03786-6.
- Miller SE, Tummers WS, Teraphongphom N, van den Berg NS, Hasan A, Ertsey RD, Nagpal S, Recht LD, Plowey ED, Vogel H, Harsh GR, Grant GA, Li GH, Rosenthal EL. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. J Neurooncol. 2018 Aug;139(1):135-143. doi: 10.1007/s11060-018-2854-0. Epub 2018 Apr 6.
- Moore LS, Rosenthal EL, Chung TK, de Boer E, Patel N, Prince AC, Korb ML, Walsh EM, Young ES, Stevens TM, Withrow KP, Morlandt AB, Richman JS, Carroll WR, Zinn KR, Warram JM. Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients. J Nucl Med. 2017 Feb;58(2):246-251. doi: 10.2967/jnumed.115.171413. Epub 2016 Sep 1.
- Morozov AO, Alyaev YG, Rapoport LM, Tsarichenko DG, Bezrukov EA, Butnaru DV, Sirota ES. Near-infrared fluorescence with indocyanine green for diagnostics in urology: initial experience. Urologia. 2017 Aug 1;84(3):197-202. doi: 10.5301/uj.5000235. Epub 2017 May 16.
- Qi S, Miao Z, Liu H, Xu Y, Feng Y, Cheng Z. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors. Bioconjug Chem. 2012 Jun 20;23(6):1149-56. doi: 10.1021/bc200596a. Epub 2012 Jun 4.
- Rosenthal EL, Kulbersh BD, Duncan RD, Zhang W, Magnuson JS, Carroll WR, Zinn K. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope. 2006 Sep;116(9):1636-41. doi: 10.1097/01.mlg.0000232513.19873.da.
- Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther. 2007 Apr;6(4):1230-8. doi: 10.1158/1535-7163.MCT-06-0741.
- Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, Strong TV, Schmalbach CE, Morlandt AB, Agarwal G, Hartman YE, Carroll WR, Richman JS, Clemons LK, Nabell LM, Zinn KR. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin Cancer Res. 2015 Aug 15;21(16):3658-66. doi: 10.1158/1078-0432.CCR-14-3284. Epub 2015 Apr 22.
- Slim N, Anbu D, Darzi A, Elson DS, Peters CJ. The use of indocyanine green and near-infrared fluorescence in the detection of metastatic lymph nodes during oesophageal and gastric cancer resection: a systematic review and meta-analysis. Surg Endosc. 2025 Jun;39(6):3525-3538. doi: 10.1007/s00464-025-11703-7. Epub 2025 Apr 18.
- Stone LD, Kasten BB, Rao S, Gonzalez ML, Stevens TM, Lin D, Carroll W, Greene B, Moore LS, Fuson A, James S, Hartman YE, McCammon S, Panuganti B, Nabell LM, Li Y, Li M, Bailey L, Rosenthal EL, Jeyarajan H, Thomas CM, Warram JM. Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer. Clin Cancer Res. 2024 Sep 13;30(18):4016-4028. doi: 10.1158/1078-0432.CCR-24-0940.
- Stone LD, Massicano AVF, Stevens TM, Warram JM, Morlandt AB, Lapi SE, Amm HM. 89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model. Sci Rep. 2022 Nov 10;12(1):19187. doi: 10.1038/s41598-022-23531-z.
- Suurs FV, Qiu SQ, Yim JJ, Schroder CP, Timmer-Bosscha H, Bensen ES, Santini JT Jr, de Vries EGE, Bogyo M, van Dam GM. Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model. EJNMMI Res. 2020 Sep 29;10(1):111. doi: 10.1186/s13550-020-00688-0.
- Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Ann Surg Oncol. 2018 Jul;25(7):1880-1888. doi: 10.1245/s10434-018-6453-2. Epub 2018 Apr 17.
- Tummers WS, Miller SE, Teraphongphom NT, van den Berg NS, Hasan A, Longacre TA, Fisher GA, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ, Rosenthal EL, Poultsides GA. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. HPB (Oxford). 2019 Jul;21(7):883-890. doi: 10.1016/j.hpb.2018.11.008. Epub 2019 Feb 2.
- van Keulen S, Nishio N, Fakurnejad S, Birkeland A, Martin BA, Lu G, Zhou Q, Chirita SU, Forouzanfar T, Colevas AD, van den Berg NS, Rosenthal EL. The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer. J Nucl Med. 2019 Jun;60(6):758-763. doi: 10.2967/jnumed.118.222810. Epub 2019 Feb 7.
- Vogt PR, Bauer EP, Graves K. Novadaq Spy Intraoperative Imaging System--current status. Thorac Cardiovasc Surg. 2003 Feb;51(1):49-51. doi: 10.1055/s-2003-37276.
- Warram JM, de Boer E, Moore LS, Schmalbach CE, Withrow KP, Carroll WR, Richman JS, Morlandt AB, Brandwein-Gensler M, Rosenthal EL. A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery. J Surg Oncol. 2015 Jul;112(1):2-8. doi: 10.1002/jso.23946. Epub 2015 Jun 12.
- Withrow KP, Gleysteen JP, Safavy A, Skipper J, Desmond RA, Zinn K, Rosenthal EL. Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg. 2007 Nov;137(5):729-34. doi: 10.1016/j.otohns.2007.06.736.
- Yamaoka T, Ohba M, Ohmori T. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int J Mol Sci. 2017 Nov 15;18(11):2420. doi: 10.3390/ijms18112420.
- Yang M, Cheng K, Qi S, Liu H, Jiang Y, Jiang H, Li J, Chen K, Zhang H, Cheng Z. Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. Biomaterials. 2013 Apr;34(11):2796-806. doi: 10.1016/j.biomaterials.2013.01.014. Epub 2013 Jan 21.
- Zinn KR, Korb M, Samuel S, Warram JM, Dion D, Killingsworth C, Fan J, Schoeb T, Strong TV, Rosenthal EL. IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol. 2015 Feb;17(1):49-57. doi: 10.1007/s11307-014-0773-9.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de novembro de 2026
Conclusão Primária (Estimado)
1 de novembro de 2027
Conclusão do estudo (Estimado)
1 de novembro de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
30 de outubro de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
30 de outubro de 2026
Primeira postagem (Real)
5 de novembro de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
5 de novembro de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
30 de outubro de 2026
Última verificação
1 de outubro de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- STUDY00000341
- UAB (Outro identificador: UAB)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Sim
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .